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Background: Diagnosis of chronic low back pain (CLBP) is traditionally predicated on identifying under-
lying pathological or anatomical causes, with treatment outcomes modest at best. Alternately, it is sug-
gested that identiﬁcation of underlying pain mechanisms with treatments targeted towards speciﬁc pain
phenotypes may yield more success. Differentiation between nociceptive and neuropathic components of
CLBP is problematic; evidence suggests that clinicians fail to identify a signiﬁcant neuropathic component
in many CLBP patients. The painDETECT questionnaire (PDQ) was speciﬁcally developed to identify occult
but signiﬁcant neuropathic components in individuals thought to have predominantly nociceptive pain.
Methods: Using the PDQ, we classiﬁed 50 CLBP patients into two distinct groups; those with predomi-
nantly nociceptive pain (Group 1) and those with a signiﬁcant neuropathic component (Group 2). We
characterised these two distinct CLBP sub-groups using a) questionnaire-based behavioural evaluation
measuring pain-related function and quality of life, pain intensity and psychological well-being and b)
sensory examination, using two-point and tactile threshold discrimination.
Objective: We sought to determine if differences in the pain phenotype of each CLBP sub-group would be
reﬂected in sensory and behavioural group proﬁles.
Results: We report that Group 1 and Group 2 sub-groups demonstrate unique clinical proﬁles with
signiﬁcant differences in sensory tactile discrimination thresholds and in a wide range of behavioural
domains measuring pain intensity, disability and psychological well-being.
Conclusion: We have demonstrated distinct clinical proﬁles for CLBP patient sub-groups classiﬁed by
PDQ. Our results give diagnostic conﬁdence in using the PDQ to characterise two distinct pain pheno-
types in a heterogeneous CLBP population.
© 2016 Published by Elsevier Ltd.1. Introduction
Heterogeneity in the clinical presentation of Chronic Low Back
Pain (CLBP) makes diagnosis and treatment challenging. CLBP
treatment pathways are traditionally predicated on identifying
pathophysiological causes, which are not possible to identify in 90%
of patients (Koes et al., 2006). Attention has focused on identifying
sub-groups within the heterogeneous CLBP population, in order totitute of Psychiatry, Psychol-
on SE5 8AF, UK.
r).
sion of the published work.more effectively target treatments (Delitto, 2005; Foster et al., 2011;
Huijnen et al., 2015; O'Sullivan, 2005; Stanton et al., 2011; Turk,
2005). These subgroups may be variously deﬁned by physiological
or psychological determinants. Alternately, it has been suggested
that identiﬁcation of underlying pain mechanisms and treatments
targeted towards speciﬁc pain phenotypes may yield more suc-
cessful outcomes (Woolf, 2004). Clinically, this is important, as pa-
tients with neuropathic pain (NeuP) demonstrate poorer outcomes
and greater comorbidities than patients with nociceptive pain
(Smith and Torrance (2012); Smith et al. (2007) Jensen et al., 2007).
The deﬁnition and diagnosis of NeuP and its differentiation from
nociceptive pain remains controversial. Current IASP guidelines
stipulate that a demonstrable lesion or disease of the somatosen-
sory nervous system is necessary in order to arrive at a deﬁnitive
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of Pain, 2016) For a full up to date description of the issues un-
derlying the diagnosis and deﬁnition of neuropathic pain see
Finnerup et al. (2016). Using the current IASP guidelines, only a
small percentage of CLBP patients can be classiﬁed as ‘neuropathic’
yet, in routine clinical practice, many patients with low back pain
present with symptoms that are indicative of a signiﬁcant neuro-
pathic component (i.e spread of pain, paroxysmal pain, dysaes-
thesia, allodynia). However, these patients may either present with
no history or conﬁrmatory evidence of a lesion or disease process,
with equivocal examination ﬁndings and with pain that is not in a
’neuroanotomically plausible’ distribution. Recent work suggests
that clinicians fail to identify signiﬁcant neuropathic components
in a number of people with LBP and that the true incidence of CLBP
patients with a signiﬁcant neuropathic component may be under-
diagnosed (Freynhagen et al., 2006). In addition, evidence shows
that neuropathic LBP is not restricted to patients that presentwith a
typical radicular presentation (Attal et al., 2011; Forster et al., 2013).
Patients with occult neuropathic symptoms may therefore be mis-
classiﬁed as nociceptive, in spite of a seemingly neuropathic
symptom proﬁle, or else idiopathic, which allows no indication of
underlying pain mechanisms. Worst of all, an idiopathic classiﬁ-
cation may hint at a pejorative ‘functional’ label to a patient's
symptoms (Cohen et al., 2011).
Importantly, failure to identify patients with occult neuropathic
components may lead to sub-optimal treatment regimes. It is
proposed that improved ability to identify these patients and target
appropriate treatments will result in better outcomes.
The PainDETECT questionnaire (PDQ)was speciﬁcally developed
to identify neuropathic components in patients with CLBP and to
differentiate LBP patients with a signiﬁcant neuropathic compo-
nent from LBP patients with predominantly nociceptive, mechan-
ical painwithout the need for physical examination or conﬁrmatory
diagnostic markers. The PDQ has been shown to have a high
sensitivity (85%), speciﬁcity, (80%) and positive predictive accuracy
(83%) in LBP (Freynhagen et al., 2006). In addition, as clinical tests
such as spinal palpation, slump testing and straight leg raising are
largely qualitative in nature and therefore suffer from variability
and limitations of sensitivity and speciﬁcity (Rubinstein and van
Tulder, 2008; van der Windt et al., 2010), identiﬁcation by PDQ
was chosen to reduce possible inconsistencies in patient selection
criteria and as a means to standardise the selection process.
We therefore chose to use the PDQ to identify two sub-groups
within our CLBP population: LBP patients with predominantly
nociceptive, mechanical pain (Group 1) and LBP patients with a
signiﬁcant neuropathic component (Group 2).
The primary objective of this study was to characterise these
two groups. Our hypothesis stated that the psychophysical clinical
proﬁles of our participants would reﬂect the clinical phenotypes
and underlying pain mechanisms of Group 2 and Group 2 patients,
identiﬁed using the PDQ. We also hypothesised that, in particular,
Group 2 patients would display a more complex proﬁle compared
to Group 1 patients. If the proﬁles of each group were truly
different, then diagnostic conﬁdence that the PDQ is a valid tool,
able to characterise pain phenotypes in a heterogeneous popula-
tion, would be strengthened.
2. Methods
2.1. Recruitment
Fifty patients with CLBP were recruited from the same inner city
London hospital, together with twenty age and sex-matched con-
trols. All patients consented to clinical proﬁling by collection of
behavioural questionnaire data, sensory examination andsubsequent structural and functional neuroimaging (no neuro-
imaging data will be shown here but will form the basis of a sub-
sequent paper).
In order to be eligible for inclusion, patients needed to report a
history of LBP for at least 12months and were required to score 3 or
above on an 11 point numerical rating scale (NRS) on the day of
screening. Subjects were excluded if they complained of chronic or
current pain conditions other than LBP or if they were currently
experiencing, or had any history of, clinically signiﬁcant or unstable
medical or psychological conditions that would compromise
participation in the study. All control subjects, were required to be
free of any painful conditions and other signiﬁcant medical and
psychological confounding factors. All subjects were screened for
MRI safety. There were no exclusion criteria for pain medication
and all subjects continued with their usual medication, which
included paracetamol, non-steroidal anti inﬂammatorymedication,
neuropathic pain medication (anti-convulsants and anti-
depressives) and opiates. Using chi-squared tests for indepen-
dence (with Yate's continuity correction), no signiﬁcantly different
levels of medication usage across all categories were found for
between groups. Further information on the recruitment process is
given in Fig. 1. Formal ethical approval for the study was granted by
XXXXX Research Ethics Committee (08/H0810/51).
Although all patients were initially selected at random, during
the later stages of the recruitment process it was observed that
more Group 1 than Group 2 patients (as determined by the PDQ)
had been recruited at the ﬁrst check point. This reﬂects the de-
mographic incidence of neuropathic pain compared to non-
neuropathic pain in clinical populations (Smith and Torrance,
2012; Torrance et al., 2006). It was therefore deemed necessary
during the latter stages of recruitment to preferentially select
Group 2 patients, as determined by PDQ, in order to balance patient
numbers between the LBP groups.
2.2. Clinical and psychometric assessments
The following questionnaires were administered in order to
assess pain, disability and psychological status: painDETECT
Questionnaire (PDQ) (Freynhagen et al., 2006), numeric rating scale
(NRS) for pain, Short Form McGill Pain Questionnaire (SFMPQ)
(Melzack, 1987), RAND Medical Outcomes 36-Item Short Form
Survey Instrument (SF-36) (Ware and Sherbourne,1992), Centre for
Epidemiologic Studies Depression Scale Questionnaire (CES-D)
(Radloff, 1977), State Trait Anxiety Inventory (STAI) (Spielberger,
1983) and the Revised Symptom Checklist 90 Questionnaire (SCL-
90-R) (Derogatis and Unger, 2010). Detailed information on each
questionnaire is provided in Table 1.
2.3. Sensory testing
Sensory evaluation was carried out using two-point discrimi-
nation (2PD) and tactile threshold discrimination (TTD). Partici-
pants were positioned comfortably in prone lying with a pillow
underneath the stomach to standardise lumbar position. The
examiner identiﬁed and marked the spine in line with the spinous
processes of L1, L3 and L5 bilaterally in line with the inferior angle
of the scapula. The same assessor examined all patients in order to
reduce the inter-rater variability inherent in these techniques
(Catley et al., 2013). Testing was undertaken separately on left and
right sides of the back and the order of testing was randomised, as
was the order of levels tested.
2.3.1. TTD testing
Semmes-Weinstein monoﬁlaments of varying thickness with
corresponding target forces (1.65, {0.008g}; 2.83, {0.07g}; 3.61,
Fig. 1. Recruitment pathway algorithm. All patients were required to attend for a single visit. All back pain patients were classiﬁed by the PainDETECT questionnaire into Group 1
and Group 2 sub-groups. All patients, including controls, underwent sensory examination and psychometric and behavioural assessment (Study One) that preceded structural
(VBM: Voxel-based morphometry) and functional neuroimaging (ASL: Arterial spin labeling) (Study Two). Details of Study Two will be reported in a separate paper.
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sure tactile sensory thresholds at the level of L1, L3 and L5 spinous
processes. Following a standardised, brief explanation of what the
ﬁlaments were, each ﬁlament was applied perpendicular to the
skin with enough force to create a visible bend in the ﬁlament.
Patients were instructed to “Say ‘TOUCH’ every time you feel the
ﬁlament on your skin”. A standardised up-down-up protocol for all
patients was carried out beginning with a 1.65, 0.008 g ﬁlament.
Filaments were applied 5 times with a 2 s delay between each
repetition. For a positive result, patients had to report that 3 out of 5
applications elicited a response for each ﬁlament (Yarnitsky, 1997).
Threshold was established by the method of limits, where stimuli
were increased stepwise in ﬁlament strength until a response was
elicited. The ﬁlament with a bending pressure immediately below
the established threshold ﬁlament was then reapplied to conﬁrm
the exact threshold (Yarnitsky, 1997).The threshold for each level
(L1, L3, L5) was recorded on a standardised body chart.2.3.2. 2PD testing
2PD threshold testing followed the principles of the ‘down-up-
down’ method described by Moberg (1990) and Seltzer and Seltzer
(1986). A set of electronic digital callipers (Precision Gold®) with a
scale measured in 1 mm gradations was lightly applied until the
ﬁrst blanching of the skin. Testing was undertaken bilaterally at
each level, and the order of the side of testing was randomised.
Based on normative data for 2PD threshold (Nolan, 1985), testing
was commenced with callipers set at 70mm. The distance between
the points was decreased in 5 mm increments until the subject was
able to perceive only one point instead of two. Each participant was
instructed to say ‘one’when they felt one point and ‘two’when they
felt two points. This was conﬁrmed by descending 5 mm below this
point. An ascending sequence was then applied in 2 mm in-
crements until the patient again reported two points. Testing
continued around these initial values using ascending and
descending sequences in 1 mm increments until a consistentresponse was obtained. Catch trials were used to verify that par-
ticipants were not guessing.
The same examiner conducted the sensory examination and
collected the questionnaire data. In order to reduce the risk of bias,
the painDETECT and other questionnaire data were not analysed
until after all the examination procedures were completed.
2.4. Data analysis
All analyses were performed using SPSS 20 (IBM SPSS Statistics
for Windows, Version 20.0. Armonk, NY: IBM Corp.).
2.4.1. Questionnaire data
Pain intensity and discrimination were examined using pain on
day of assessment NRS and all domains of the SFMPQ outcome
measures. Independent samples t-tests were used to identify dif-
ferences between Group 1 and Group 2 groups. Pain-related func-
tional status and quality of life were assessed using all domains of
the SF-36. Psychological well-being was assessed using all domains
of the SCL-90-R, CES-D and STAI. One-way between groups analysis
of variance (ANOVA) was used to identify differences between all
three groups (controls, Group 1, and Group 2). Planned compari-
sons were then used to test the primary hypotheses that CLBP
patients suffer greater psychological distress and poorer quality of
life compared to controls and that Group 2 patients suffer greater
psychological distress and poorer quality of life compared to Group
1 patients. Homogeneity of variance across groups was tested for
using Levene's test. Post-hoc and t-tests and planned contrast re-
sults were adjusted if homogeneity of variance was violated. Due to
the large number of comparisons undertaken, post ehoc correction
using the BenjaminieHochberg procedure (Benjamini and Hochberg,
1995) was applied to the subgroup data containing multiple do-
mains order to correct for type-1 errors. To facilitate understanding
of the clinical signiﬁcance of each ﬁnding in relation to our CLBP
subgroups, we also calculated Cohen's d, a standardised measure of
Table 1
Description of behavioural questionnaires used including questionnaire constructs, domains and details of scoring.
Name Construct Intended to measure Domains Scoring Comments
Numeric Rating Scale (NRS) Pain intensity n/a 11 point scale, 0e10
Short Form McGill Pain
Questionnaire (SFMPQ)
(Melzack, 1987)
Multidimensional measure of
pain
Measures a) sensory and b)
affective dimensions of the pain
experience.
Also includes ﬁve-item present
pain intensity scale (PPI) to
describe overall pain intensity
and 10-cm visual analogue scale
(VAS).
Intensity scale from 0 (none) to 4
(severe).
Widely used in adult chronic pain
populations, including CLBP
(Ruoff et al., 2003) and has
modest predictability in
discrimination of neuropathic
and musculoskeletal pain of
spinal cord injury (Putzke et al.,
2002).
Rand Medical Outcomes 36-
Item Short Form Survey
Instrument (SF-36) (Ware
and Sherbourne, 1992)
General health related quality of
life questionnaire.
Measures: 1) limitations in
physical activities because of
health problems (SF-36 Physical
Function); 2) limitations in social
activities because of physical or
emotional problems (SF-36 Social
Function); 3) limitations in usual
role activities because of physical
health problems (SF-36 Role-
Physical); 4) bodily pain (SF-36
Pain); 5) psychological distress
and emotional well-being (SF-36
General Mental Health); 6)
limitations in usual role activities
because of emotional problems
(SF-36 Role-Emotional); 7)
energy and fatigue (SF-36
Vitality); 8) general health
perceptions (SF-36 General
Health).
For each of the eight domains an
aggregate percentage score is
produced. The percentage scores
range from 0% (lowest or worst
possible level of functioning) to
100% (highest or best possible
level of functioning). Two
summary scores of physical
quality of life (Physical
Component Summary; PCS) and
psychological well-being and
general health perception
(Mental Component summary;
MCS) can also be obtained by
combining physical and mental
domains respectively (Ware
et al., 1995). PCS and MCS scales
are scored to have the same
average (50) and standard
deviation (10) (norm-based
scores). Therefore scores below
and above 50 represent above
and below average values of
physical and mental health and
functioning with increasingly
low scores represent increasing
degrees of psychological distress
and disability (Ware et al.,
1993). A cut off score of 35 or less
on the MCS is able to identify
depressive symptoms (as
measured by the CES-D) in LBP
patients (Walsh et al., 2006).
Widely used measure of health-
related quality of life; has been
shown to discriminate between
subjects with different chronic
conditions and between
subjects with different severity
levels of the same disease
(Kosinski et al., 1999)
Centre For Epidemiologic
Studies Depression Scale
Questionnaire (CES-D)
(Radloff, 1977)
20-item questionnaire of
symptoms associated with
depression
Scores range from 0 to 60, with
high scores indicating greater
depressive symptoms. It cannot
be used to diagnose depression in
itself. However, scores of 16 or
greater can be used to identify
individuals at risk for clinical
depression in primary care and
19 or greater in the chronic pain
population (Turk and Okifuji,
1994).
State Trait Anxiety Inventory
(STAI) (Spielberger, 1983)
Anxiety Measures two components of
anxiety: Anxiety in the present
moment (“state”) and anxiety as
a general, ongoing personal
characteristic (“trait”).
Twenty questions are each scored
on a four point Likert scale;
higher scores are associated with
higher levels of anxiety. A cut-
point of 39e40 is normally used
for clinically signiﬁcant
symptoms of a state of anxiety
(Julian, 2011; Knight et al.,
1983)
Revised
Symptom Checklist 90
Questionnaire (SCL-90-R)
(Derogatis and Unger, 2010)
The SCL-90 is designed to assess a
broad range of psychological
problems and the current
psychopathology of subjects
along nine symptom constructs.
Symptom constructs:
Somatisation, Obsessive-
Compulsive Symptoms,
Interpersonal Sensitivity,
Depression, Anxiety, Hostility,
Phobic-Anxiety, Paranoid
Ideation and Psychoticism. Three
additional scales have also been
developed; the Positive Symptom
Total (PST) measuring the total
number of self reported
symptoms, the Positive Symptom
90-item questionnaire:
Raw scores are calculated by
dividing the sum of scores for a
domain by the number of items
in the domain. The global
severity index is computed by
summing the scores of the nine
domains and additional items
and then dividing by the total
number of responses. Scores are
converted to standard T-scores
using the norm group
(continued on next page)
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Table 1 (continued )
Name Construct Intended to measure Domains Scoring Comments
Distress Index (PSDI) measuring
intensity of symptoms and the
Global Severity Index (GSI),
designed to measure overall
psychological distress which can
be used as a summary of the test.
appropriate for the patient.
The SCL-90-R scoring manual
contains normative data for
psychiatric outpatients,
psychiatric inpatients, adult
non-patients, adolescent non-
patients (http://www.
pearsonclinical.co.uk) (Schmitz
et al., 2000)
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by which the two groups differ. An effect size of <0.2 is considered
’small’, 0.5 ¼ moderate and >0.8 ¼ large (Cohen, 1988).
2.4.2. Sensory examination data
Mean 2PD and TTD values for all points recorded on the back
were calculated for each individual. One-way analysis of variance
testing (ANOVA) was used to examine group differences in 2PD and
TTD examination scores. Planned comparisons were then used to
test the primary hypothesis that 2PD is disrupted in CLBP partici-
pants compared to control patients, and also in Group 2 compared
to Group 1 patients. The same planned comparisons were applied
to the TTD data and Cohen's d effect sizes were also calculated.
3. Results
3.1. Demographics
3.1.1. painDETECT
After recruitment patients were classiﬁed into Group 1 and
Group 2 subgroups using the PDQ. Patients scoring less than 19
were classiﬁed as likely to have nociceptive mechanical low back
pain (Group 1, n ¼ 26); patients scoring 19 or more were classiﬁed
as likely to have a signiﬁcant neuropathic component to their pain
(Group 2 n ¼ 24). This cut-off value is based on the classiﬁcation
established by Freynhagen (Freynhagen et al., 2006). The mean
painDETECT score for Group 1 was 9.0 (SD 5.15) and for Group 2 it
was 23.9 (SD 4.36).
3.1.2. Age
Patients varied from 21 to 59 years in age (mean ¼ 39 years, SD
9.91). There was no signiﬁcant difference in age across groups
(ANOVA F (2, 65) ¼ 2.4, p ¼ 0.10).
3.1.3. Duration of pain symptoms
Duration of LBP across LBP patients varied from 12 to 360
months. Qualitatively, there was little clinically relevant difference
in duration of pain symptoms across the groups. Mean duration of
pain symptoms in Group 1 patients was 102 months (median, 54
months), and for Group 2 patients it was 98 months (median, 72
months).
3.2. Clinical and psychometric assessment
3.2.1. Measures of pain
Using Student's t-test, Group 2 patients reported signiﬁcantly
higher examination day pain than Group 1 patients as measured by
NRS. Group 2 patients also demonstrated signiﬁcantly greater
SFMPQ VAS pain scores, signiﬁcantly greater SFMPQ Sensory Pain
Descriptor Scale scores and signiﬁcantly greater SFMPQ Present
Pain Intensity scale scores than patients with Group 2. Mean scores
and standard deviation values for all groups, as well as values of the
student's T-statistic and associated signiﬁcance values and Cohen'sd are described in Table 2. There was no signiﬁcant difference in
McGill Affective Pain Scores between Group 1 and Group 2 groups;
however only 35 Scores were completed (Group 1 N ¼ 20, Group
2 N ¼ 15) due to an administrative error (see Table 2).
3.3. Measures of function and quality of life
Using one-way analysis of variance (ANOVA) with planned
comparisons to identify differences across subject groups, CLBP
patients experienced signiﬁcantly poorer physical and mental
health related quality of life compared to controls as measured by
all domains of the SF-36 (see Table 3). CLBP patients also exhibited
signiﬁcantly greater signs of anxiety (STAI), depression (CES-D) and
psychological distress across all domains of the SCL-90-R (see
Table 4).
Group 2 patients experienced signiﬁcantly poorer physical and
mental health related quality of life compared to Group 1 patients
as measured by the following domains of the SF-36: Physical
functioning, Bodily pain, Physical component summary, Vitality,
Social functioning, General mental health and the Mental compo-
nent summary (see Table 3).
Compared to Group 1 patients, Group 2 patients also exhibited
greater signs of depression (CES-D) and psychological distress
across the following SCL-90-R psychological domains: Somatisa-
tion, Interpersonal sensitivity, Anxiety, Phobic anxiety, Global
severity index and Positive symptom total (see Table 4).
3.4. Sensory examination
Using ANOVA with planned comparisons, TTD examination
scores revealed signiﬁcantly increased sensory thresholds to tactile
stimulation (t (62) ¼ 2.23, p ¼ 0.029) indicating loss of tactile
sensitivity and signiﬁcantly increased thresholds to two-point
discrimination in CLBP patients compared to controls (t
(62) ¼ 3.30, p ¼ 0.002). In addition, we observed that TTD ex-
amination scores revealed signiﬁcantly increased sensory thresh-
olds to tactile stimulation in Group 2 compared to Group 1 patients
(t (62) ¼ 2.84, p ¼ 0.006). However, there were no signiﬁcant
differences between Group 2 and Group 1 groups in 2PD exami-
nation scores (t (62)¼0.06, p¼ 0.973). Mean scores and standard
deviation values for groups, as well as values of the Student's T-
statistic and associated signiﬁcance values are shown in Table 5.
4. Discussion
The current study revealed signiﬁcant differences in sensory
examination and behavioural and psychometric data in a group of
CLBP patients compared to controls and between neuropathic and
non-neuropathic CLBP subgroups, as determined by the PDQ. CLBP
patients reported signiﬁcantly poorer physical and mental health
related quality of life compared to controls across all SF-36 do-
mains, greater psychological distress in all SCL-90-R domains and
also greater signs of anxiety (STAI) and depression (CES-D). CLBP
Table 2
Pain Scores: Mean scores (Mean) and standard deviation (SD) values of Numeric Rating Scale (NRS) for Pain & Short FormMcGill Pain Questionnaire (SFMPQ) for CLBP groups,
including values of the student's T-statistic with associated signiﬁcance values and Cohen's d effect sizes for comparisons between Group 1 and Group 2 patients. No pain data
were collected for control subjects, as recruitment required them to be pain-free. Original signiﬁcance values are described alongside BenjaminieHochberg post ehoc
correction values. All data, except signiﬁcance values, have been corrected to 2 decimal places. *Statistically signiﬁcant difference (p < 0.05), ** Statistically signiﬁcant difference
(p < 0.001).
Questionnaire Domain Controls
(Mean, SD)
NocLBP
(Mean, SD)
NuLBP
(Mean, SD)
CLBP & Controls Group 1 & Group 2
t value df Sig. value t value df Uncorrected
Sig. value
B-H corrected
Sig. value
Cohen's d
NRS e e 4.62 2.06 6.88 1.7 e e e 4.21 48.00 <0.001** <0.001** 1.21
SFMPQ VAS e e 61.77 18.89 80.68 12.75 e e e 3.99 46.00 <0.001** <0.001** 1.18
Sensory Pain Descriptors e e 10.19 5.87 19.77 7.53 e e e 4.95 46.00 <0.001** <0.001** 1.46
Affective Pain Descriptors e e 3.45 2.33 4.93 2.66 e e e 1.76 33.00 0.088 0.44 0.09
Present Pain Intensity e e 2.46 0.81 3.71 1.19 e e e 4.12 34.02 <0.001** <0.001** 1.23
Table 3
SF-36 Scores measuring health related quality of life: Mean scores (Mean) and standard deviation (SD) values of RAND Medical Outcomes 36-Item Short Form Survey In-
strument (SF-36) for all groups, including values of planned comparisons t values with associated signiﬁcance values and Cohen's d effect sizes for comparisons between CLBP
and Controls and Group 1 and Group 2 patients. Original signiﬁcance values are described alongside BenjaminieHochberg post ehoc correction values. All data, except sig-
niﬁcance values, have been corrected to 2 decimal places. *Statistically signiﬁcant difference (p < 0.05), ** Statistically signiﬁcant difference (p < 0.001).
Questionnaire Domain Controls
(Mean, SD)
NocLBP
(Mean, SD)
NuLBP
(Mean, SD)
CLBP & Controls Group 1 & Group 2
t value df Sig. value t value df Uncorrected
Sig. value
B-H corrected
Sig. value
Cohen's d
SF-36 Physical Functioning 100.00 0.00 55.38 20.63 35.43 19.42 19.07 46.81 <0.001** 3.49 46.81 0.001* 0.002* 1.02
Role-Physical 100.00 0.00 36.54 40.76 26.09 38.05 12.20 46.85 <0.001** 0.93 46.85 0.358 0.397 0.27
Bodily Pain 98.95 3.15 41.54 19.08 24.13 16.95 24.73 53.84 <0.001** 3.38 47.00 0.001* 0.002* 0.99
General Health Perception 85.53 10.39 52.88 19.86 47.61 25.67 8.65 58.88 <0.001** 0.80 41.28 0.43 0.428 0.23
PCS 96.12 2.60 46.59 19.12 33.32 19.10 20.07 50.49 <0.001** 2.43 46.28 0.019* 0.022* 0.71
Vitality 73.95 14.20 48.08 22.45 36.30 18.48 6.15 65.00 <0.001** 2.15 65.00 0.035* 0.04* 0.63
Social Functioning 96.71 11.67 65.38 23.53 42.93 19.15 10.48 57.66 <0.001** 3.68 46.70 0.001* 0.001* 1.07
Role-Emotional 94.74 12.49 70.51 40.36 47.83 42.43 5.40 60.94 <0.001** 1.91 45.60 0.062 0.07 0.56
General Mental health 81.68 10.27 71.23 16.93 58.96 17.94 4.83 54.19 <0.001** 2.45 45.48 0.018* 0.022* 0.71
MCS 86.77 7.51 63.80 21.10 46.51 18.41 9.56 64.98 <0.001** 3.06 46.99 0.004* 0.005* 0.89
Table 4
Psychometric scores: Mean scores and standard deviation values of Centre for Epidemiologic Studies Depression Scale Questionnaire (CES-D), State Trait Anxiety Inventory
(STAI) and the Revised Symptom Checklist 90 Questionnaire (SCL-90-R) for all groups, including values of planned comparisons t values with associated signiﬁcance values and
Cohen's d effect sizes for comparisons between CLBP and Controls and Group 1 and Group 2 patients. Original signiﬁcance values are described alongside BenjaminieHochberg
postehoc correction values. All data, except signiﬁcance values, have been corrected to 2 decimal places. *Statistically signiﬁcant difference (p< 0.05), ** Statistically signiﬁcant
difference (p < 0.001).
Questionnaire Domain Controls
(Mean, SD)
NocLBP
(Mean, SD)
NuLBP
(Mean, SD)
CLBP & Controls Group 1 & Group 2
t value df Sig. value t value df Uncorrected
Sig. value
B-H corrected
Sig. value
Cohen's d
SCL-90-R Somatisation 42.68 9.10 62.69 9.12 69.58 9.38 9.45 66.00 <0.001** 2.65 66 0.01* 0.015* 0.76
Obsessive-Compulsive 50.00 10.29 59.77 10.45 65.21 9.97 4.52 66.00 <0.001** 1.88 66 0.065 0.074 0.54
Interpersonal Sensitivity 46.63 6.33 53.12 12.43 61.38 12.36 4.66 60.39 <0.001** 2.35 47.72 0.023* 0.029* 0.68
Depression 47.32 10.61 56.92 11.29 62.48 12.91 3.92 65.00 <0.001** 1.66 65 0.102 0.113 0.48
Anxiety 42.53 8.26 51.85 11.98 60.46 14.23 5.12 50.86 <0.001** 2.31 45.17 0.026* 0.030* 0.67
Hostility 44.79 7.42 53.27 11.33 55.38 13.86 3.85 53.63 <0.001** 0.59 44.54 0.561 0.609 0.17
Phobic Anxiety 46.89 7.98 50.54 11.17 58.96 13.08 3.12 48.95 0.003* 2.44 45.45 0.019* 0.025* 0.70
Paranoid Ideation 46.21 7.71 49.62 10.23 54.04 15.00 2.21 50.97 0.032* 1.21 40.16 0.234 0.257 0.35
Psychoticism 45.63 4.55 55.85 11.38 62.25 13.39 6.55 63.15 <0.001** 1.82 45.35 0.076 0.085 0.53
Global Severity Index 43.84 11.21 58.27 9.99 65.17 10.45 6.32 66.00 <0.001** 2.32 66 0.023* 0.028* 0.67
Positive Symptom Total 43.89 9.36 54.85 10.02 63.26 8.97 5.91 65.00 <0.001** 3.10 65 0.004* 0.006* 0.9
Positive Symptom
Distress Index
46.58 8.58 61.31 9.95 62.42 10.48 5.79 66.00 <0.001** 0.40 66 0.69 0.69 0.12
STAI State 29.53 9.65 36.42 8.02 43.83 14.34 3.83 37.88 <0.001** 2.23 35.49 0.032* 0.064 0.65
Trait 32.80 8.08 42.31 10.13 46.63 11.18 4.42 67.00 <0.001** 1.53 67 0.131 0.261 0.44
CES-D 4.55 5.69 11.42 8.37 23.33 10.67 6.88 55.70 <0.001** 4.37 43.60 <0.001** <0.001** 1.26
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examination thresholds compared to controls.
Group 2 patients reported signiﬁcantly greater examination day
pain using NRS and signiﬁcantly greater pain (SFMPQ VAS, Sensory
Pain Descriptor Scale Present Pain Intensity scale) scores than pa-
tients in Group 1. Group 2 patients experienced signiﬁcantly poorerphysical and mental health related quality of life compared to
Group 1 patients (SF-36 domains of Physical functioning, Bodily
pain, Vitality, Social functioning, General mental health, Mental
component summary and Physical component). Group 2 patients
also exhibited greater signs of depression (CES-D) and psycholog-
ical distress across SCL-90-R domains (Somatisation, Interpersonal
Table 5
Sensory Examination Scores: Mean scores (Mean) and standard deviation (SD) values of two-point discrimination (2PD) and tactile threshold discrimination (TTD) scores. 2PD
scores are in centimetres. Tactile threshold discrimination (TTD) values aremeans of tactile threshold sensitivity values corresponding to ﬁlament thickness. Values of planned
comparisons t values with associated signiﬁcance values and Cohen's d effect sizes for comparisons between CLBP and Controls and Group 1 and Group 2 patients are reported.
All data, except signiﬁcance values have been corrected to 2 decimal places. *Statistically signiﬁcant difference (p < 0.05).
Test Controls (Mean, SD) MLBP (Mean, SD) NuLBP (Mean, SD) CLBP & Controls MLBP & NuLBP
t value df Sig. value t value df Sig. value Cohen's d
TTD 2.70 0.67 2.85 0.78 3.48 0.78 2.23 62 0.029* 2.84 62 0.006* 0.72
2PD 4.98 0.65 6.47 1.83 6.46 1.89 3.30 61 0.002* 0.03 61 0.973 0.01
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Positive symptom total) compared to Group 1 patients. TTD ex-
amination scores revealed signiﬁcantly increased sensory thresh-
olds to tactile stimulation in Group 2 compared to Group 1 patients.
The following discussion will focus on the clinical implications
of these data in relation to the assessment of underlying pain
phenotypes in CLBP, centering on discussions surrounding the
deﬁnition of neuropathic pain and in particular, the use of
screening questionnaires as aids to diagnosis.
4.1. Re-thinking classiﬁcation of underlying pain mechanisms in
CLBP
In this study, we have described CLBP patients with PDQ scores
above 18 as having ‘a signiﬁcant neuropathic component’ to their
LBP as recommended by Freynhagen et al. (2006). This does not
necessarily imply that these patients present with well-deﬁned
radicular symptoms and an identiﬁable nerve root lesion. Evi-
dence shows that many patients with a diagnosis of non-speciﬁc
low back pain have a signiﬁcant neuropathic component to their
pain (Freynhagen et al., 2006) and patients within our Group 2
cohort may fail to conform to the current IASP deﬁnition of
neuropathic pain, which explicitly states that without evidence of a
conﬁrmatory lesion or disease process, signs or symptoms alone
cannot justify the use of the term ‘neuropathic’. However, wewould
suggest that these patients present with a signiﬁcant neuropathic
component to their pain, irrespective of any lesion or pathological
status. Our sensory examination ﬁndings support the idea that
symptoms in the Group 2 group are unlikely to be mediated by a
peripheral nerve neuritis or neuropathy as a predictable pattern of
sensory loss was not observed. Studies on the sequelae of a mixed
peripheral nerve compression show an order of events governed by
nerve diameter size starting with large diameter Ad ﬁbres and the
largest Ab ﬁbres (Nygaard and Mellgren, 1998; Rydevik et al., 1984;
Yamashita et al., 2002). Damage to these ﬁbres results in a selective
loss of vibration sense, proprioception and 2PD with resulting al-
terations in sensory testing thresholds. Increasing nerve compres-
sion affects the smaller diameter Ab ﬁbres transducing light touch,
resulting in increases to tactile thresholds. The Group 2 patients in
our study demonstrated increased tactile thresholds compared to
Group 1 patients while 2PD thresholds were unaffected, making a
diagnosis of a compression neuropathy unlikely.
The current ﬁndings therefore suggest possible supraspinal
rather than peripheral mechanisms. The emergent pattern might
suggest unwelcome pathology of the CNS, for instance multiple
sclerosis, perhaps affecting transmission of sensory input via the
dorsal columns. However, this was extremely unlikely to be the
cause in our group of patients who, notwithstanding a diagnosis of
CLBP, were otherwise healthy and not suffering from any other
signiﬁcant medical or psychological conditions. In addition, all
brain scans were screened by a radiologist for signs of abnormal
pathology. We propose, therefore, that a more likely explanation is
that these ﬁndings most likely reﬂect neuroplastic alterations to
representational areas in the somatosensory cortex that areconsistent with work showing changes in representational ﬁelds
associated with alterations in 2PD thresholds (Flor, 1995; Flor et al.,
1995; Juottonen et al., 2002; Lotze et al., 2001; Maihofner et al.,
2003, 2005; Pleger et al., 2004). Supraspinal alterations in grey
matter have been demonstrated in both nociceptive and non-
nociceptive back pain (Apkarian et al., 2004). Although evidence
shows that 2PD is associated with supraspinal neuroplasticity, 2PD
was not able to discriminate between back pain subgroups in this
study.
Interpretation of our data reﬂects the ongoing debate within the
ﬁeld as to the deﬁnition of NuP. Neuropathic Pain is a clinical
description, not a diagnosis (Jensen et al., 2011). Our work lends
support to the recent recommendation to reconﬁgure the ‘noci-
ceptive-neuropathic dichotomy’ that characterises assessment of
underlying pathophysiological mechanisms in chronic pain (Kosek
et al., 2016). The authors suggest a 3rd mechanistic descriptor for
chronic pain states that are neither nociceptive (as no evidence for
actual or threatened tissue damage exists), nor neuropathic (as
there is no evidence of a lesion or disease state) but are charac-
terised by altered nociception. In particular, we suggest that our
data support the view that maladaptive functioning of the nervous
system, which was reﬂected in the term ‘dysfunction’, dropped
from the IASP deﬁnition in 2011 (Jensen et al., 2011), may underlie
the altered nociception resulting in chronic neuropathic pain-like
signs and symptoms in CLBP. We believe that the current IASP
classiﬁcation criteria for neuropathic LBP is too restrictive and may
fail to identify patients whose symptoms do not ﬁt within current
categories of nociceptive and neuropathic. We therefore support
the notion of a 3rd descriptor to classify the underlying pain
mechanisms of patients who present with symptoms suggestive of
alterations in nociceptive function.
4.2. Sub-groups of CLBP patients selected by painDETECT reﬂect
different pain phenotypes
We hypothesised that patients with CLBP would exhibit poorer
quality of life, greater psychological distress and also exhibit
different sensory examination proﬁles compared to controls. In
addition, we hypothesised that CLBP patients identiﬁed by PDQ as
having a signiﬁcant neuropathic component to their pain (irre-
spective of lesion or disease status) would complain of greater pain,
poorer quality of life, greater psychological distress and also exhibit
different sensory examination proﬁles compared to Group 1 pa-
tients. Our data supported these hypotheses; group proﬁles reﬂect
pain phenotypes identiﬁed by the PDQ. However, it may be sug-
gested that group differences may be determined by other factors.
For instance, psychological proﬁles and pain intensity differed in
each group signiﬁcantly. However, scores on the PDQ are not
determined by any sort of psychological enquiry, nor are there any
questions that assess pain intensity, so CLBP categorisation by PDQ
is independent of these parameters. We believe, therefore, that
these group differences reﬂect underlying pain mechanisms iden-
tiﬁed by the PDQ and are consistent with the concept of neuro-
pathic signs and symptoms in LBP being a consequence of
N. Spahr et al. / Musculoskeletal Science and Practice 27 (2017) 40e48 47maladaptive plasticity of the nervous system and not solely a
consequence of a lesion or disease process. In fact, it may be argued
that maladaptive central nervous system neuroplasticity may be
considered a disease process in its own right (Henry et al., 2011;
May 2008; Tracey and Bushnell, 2009).
5. Conclusion
People with neuropathic pain report signiﬁcantly higher pain
and disability scores, reduced quality of life and higher psycho-
logical co-morbidities compared to non-neuropathic pain patients
(Freynhagen et al., 2006; Jensen et al., 2007; Smith and Torrance,
2012; Smith et al., 2007). Recent work indicates that current clin-
ical examination methods and characterisation paradigms may fail
to detect neuropathic components in many patients with LBP with
both axial and distal presentations (Freynhagen et al., 2006). The
issues raised from this body of work are central to debates on the
deﬁnition, diagnosis and categorisation of neuropathic pain that
have taken place between members of the International Associa-
tion for the Study of Pain (IASP) over the last 15 years.
The primary aim of this study was to improve characterisation
and clinical proﬁling of patients with CLBP. These results not only
show signiﬁcant differences in the clinical proﬁles of CLBP patients
compared to controls, but importantly show that CLBP patients
with a signiﬁcant neuropathic component (Group 2) determined by
PDQ, differ in clinical proﬁle to patients with predominantly noci-
ceptive, mechanical symptoms (Group 1). These data demonstrate
that there are distinct differences in the clinical proﬁles of patients
whose diagnosis of neuropathic LBP rests on assessment of symp-
tom proﬁles, rather than by evidence of a lesion or disease process
and whose symptomsmay be caused by an underlyingmaladaptive
plasticity of the nervous system. These data support the use of the
PDQ as a quick and easy-to-use tool to aid to diagnosis in a clinical
setting when used as an adjunct to expert clinical examination.
Diagnostic uncertainty is coupled with poor clinical outcomes
for treatment (Torrance et al., 2006). A failure to identify patients
with occult neuropathic symptoms may lead to inappropriate tar-
geted treatments directed towards somatic tissue, resulting in un-
necessary ongoing pain, disability and suffering (Gore et al., 2007).
There is therefore an urgent need to develop more effective
assessment strategies to identify and better differentiate neuro-
pathic from mechanical low back pain. Ultimately, improved
diagnostic efﬁciency and more accurate differentiation of me-
chanical and neuropathic components in LBP may lead to appro-
priately targeted treatment strategies and therefore improved
outcomes. An important direction for further research will be to
explore stratiﬁed treatment pathways for each group.
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